Australian Natural Therapeutics Group (ANTG) has appointed adjunct research fellow at Western Sydney University (WSU) Justin Sinclair as chief scientific officer.
Sinclair will work on projects including pre-clinical research with the University of Newcastle around the potential of ANTG’s Eve Cannabis to kill or inhibit cancer cells, and a partnership with WSU’s NICM Health Research Institute on using cannabis-based medicine to improve cognitive function.
He will also continue his own doctoral research on medicinal cannabis for endometriosis and will head up the development of a compassionate access program at ANTG.
ANTG CEO Matt Cantelo said: “Attracting Mr Sinclair to the team is a real win for the company, he is one of the leading educators in Australia on the topics of cannabis and the endocannabinoid system.”
Sinclair said the current stigma surrounding medicinal cannabis consumption needs to change: “The first step is going to be the de-stigmatisation of medicinal cannabis. In the not-too-distant future we will see it accepted as an everyday medical treatment. Because of the high standards in Australia, it will also be a major export.”
He added: “Quality assurance is absolutely imperative and it’s something I’m very passionate about.”
ANTG was recently issued the country’s first GACP and GMP-accreditation, it produces four high-quality strains of cannabis flower as well as oil extract for research and clinical trials and is working on a A$92 million, 10-year export deal with the European Union.